Therapeutic drug monitoring of clozapine: An unexpected outcome

Therapeutic Drug Monitoring

Volumn 22, Issue 3, 2000, Pages 323-324

  Uges, Donald R A ^a   Boom, Katja ^a   Wientjes, Gijs D ^b   Versteege, John ^b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b Department of Psychotic Disorders   (Netherlands)

Author keywords

Cause of death; Clozapine; Poisoning; Therapeutic drug monitoring

Indexed keywords

AMOXICILLIN; CHLORDIAZEPOXIDE; CLOZAPINE; PARACETAMOL;

ADULT; ARTICLE; CASE REPORT; DEPRESSION; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG MONITORING; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; HUMAN TISSUE; LIVER FAILURE; PRIORITY JOURNAL; SEIZURE; SEPTICEMIA; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; CLOZAPINE; DRUG MONITORING; FEMALE; HUMANS; LIVER NEOPLASMS; MIDDLE AGED;

EID: 0034120104     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200006000-00015     Document Type: Article

References (14)

1. Olesen OV, Thomsen K et al. Clozapine serum levels and the side effects during steady state treatment of schizophrenic patients; a cross-sectional study. Psychopharmacology 1995;117:371-378.
2. Preskorn SH, Burke MJ, Fast GA. Therapeutic drug monitoring; principle and practice. Psychiatr Clin North Am 1993;16(3):611-649.
3. Drug evaluation monographs clozapine. LPT3, April 12, 1999
4. Martindale, The Extra Pharmacopoeia. Clozapine. London: the Royal Pharmaceutical Society; 1996:31:697-699.
5. Loosdrecht Van de AA, Faber HJ, Hordijk P, Uges DRA, Smit A. Clozapine-induced agranulocytosis: a case report. Immunopathologic considerations. Neth J Med 1998;52:26-29.
6. Schulz M and Schmoldt A. Therapeutic and toxic blood concentrations of more than 500 drugs. Pharmazie 1997;52(12):845-911.
7. Maestri G, Piccini G et al. Acute clozapine overdosage. Br J Psychiatry 1997:170;290.
8. Broich K, Heinrich S, Marneros A. Acute clozapine overdosage; plasma concentration and outcome. Pharmacopsychiatry 1998;31: 149-151.
9. Gerson SL, Meltzer H. Mechanism of clozapine-induced agranulocytosis. Drug Saf 1992;7:17-25.
10. Fang J, Coutts RT, McKenna KF, Baker GB. Elucidation of individual cytochrome P450 enzymes involved in the metabolism of clozapine. Naunyn-Schmiedeberg*s Arch Pharmacol 1998;358: 592-599.
11. Pimohamed M, Williams D et al. Metabolism and bioactivation of clozapine by human liver in vitro. J Pharmacol Exp Ther 1995;272(3);984-990.
12. Taylor D. Pharmacokinetic interactions involving clozapine. Br J Pscyhiatry 1997;171:109-112.
13. Hoigné R, Lawson DH, Weber E. Risk factors for adverse drug reactions - epidemiological approaches. Eur Clin Pharmacol 199;39:321-325.
14. Shearman DJC, Finlayson NDC. Disease of the gastrointestinal tract and the liver. 2nd ed. Edinburgh: Churchill Livingstone; 1989: 605.